BACKGROUND: Severe gonadal steroid deficiency induces bone loss in adult men; however, the specific roles of androgen and estrogen deficiency in hypogonadal bone loss are unclear. Additionally, the threshold levels of testosterone and estradiol that initiate bone loss are uncertain. METHODS:One hundred ninety-eight healthy men, ages 20-50, receivedgoserelin acetate, which suppresses endogenous gonadal steroid production, and were randomized to treatment with 0, 1.25, 2.5, 5, or 10 grams of testosterone gel daily for 16 weeks. An additional cohort of 202 men was randomized to receive these treatments plus anastrozole, which suppresses conversion of androgens to estrogens. Thirty-seven men served as controls and receivedplacebos for goserelin and testosterone. Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA), and BMD by quantitative computed tomography (QCT) were assessed in all men. Bone microarchitecture was assessed in 100 men. RESULTS: As testosterone dosage decreased, the percent change in C-telopeptide increased. These increases were considerably greater when aromatization of testosterone to estradiol was also suppressed, suggesting effects of both testosterone and estradiol deficiency. Decreases in DXA BMD were observed when aromatization was suppressed but were modest in most groups. QCT spine BMD fell substantially in all testosterone-dose groups in which aromatization was also suppressed, and this decline was independent of testosterone dose. Estradiol deficiency disrupted cortical microarchitecture at peripheral sites. Estradiol levels above 10 pg/ml and testosterone levels above 200 ng/dl were generally sufficient to prevent increases in bone resorption and decreases in BMD in men. CONCLUSIONS: Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00114114. FUNDING: AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.
RCT Entities:
BACKGROUND: Severe gonadal steroid deficiency induces bone loss in adult men; however, the specific roles of androgen and estrogen deficiency in hypogonadal bone loss are unclear. Additionally, the threshold levels of testosterone and estradiol that initiate bone loss are uncertain. METHODS: One hundred ninety-eight healthy men, ages 20-50, received goserelin acetate, which suppresses endogenous gonadal steroid production, and were randomized to treatment with 0, 1.25, 2.5, 5, or 10 grams of testosterone gel daily for 16 weeks. An additional cohort of 202 men was randomized to receive these treatments plus anastrozole, which suppresses conversion of androgens to estrogens. Thirty-seven men served as controls and received placebos for goserelin and testosterone. Changes in bone turnover markers, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA), and BMD by quantitative computed tomography (QCT) were assessed in all men. Bone microarchitecture was assessed in 100 men. RESULTS: As testosterone dosage decreased, the percent change in C-telopeptide increased. These increases were considerably greater when aromatization of testosterone to estradiol was also suppressed, suggesting effects of both testosterone and estradiol deficiency. Decreases in DXA BMD were observed when aromatization was suppressed but were modest in most groups. QCT spine BMD fell substantially in all testosterone-dose groups in which aromatization was also suppressed, and this decline was independent of testosterone dose. Estradioldeficiency disrupted cortical microarchitecture at peripheral sites. Estradiol levels above 10 pg/ml and testosterone levels above 200 ng/dl were generally sufficient to prevent increases in bone resorption and decreases in BMD in men. CONCLUSIONS: Estrogens primarily regulate bone homeostasis in adult men, and testosterone and estradiol levels must decline substantially to impact the skeleton. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00114114. FUNDING: AbbVie Inc., AstraZeneca Pharmaceuticals LP, NIH.
Authors: P J Snyder; H Peachey; P Hannoush; J A Berlin; L Loh; J H Holmes; A Dlewati; J Staley; J Santanna; S C Kapoor; M F Attie; J G Haddad; B L Strom Journal: J Clin Endocrinol Metab Date: 1999-06 Impact factor: 5.958
Authors: Sundeep Khosla; L Joseph Melton; Sara J Achenbach; Ann L Oberg; B Lawrence Riggs Journal: J Clin Endocrinol Metab Date: 2005-12-20 Impact factor: 5.958
Authors: C Carani; K Qin; M Simoni; M Faustini-Fustini; S Serpente; J Boyd; K S Korach; E R Simpson Journal: N Engl J Med Date: 1997-07-10 Impact factor: 91.245
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: Amanda J Notini; Julie F McManus; Alison Moore; Mary Bouxsein; Mark Jimenez; W S Maria Chiu; Vaida Glatt; Barbara E Kream; David J Handelsman; Howard A Morris; Jeffrey D Zajac; Rachel A Davey Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Katrien Venken; Karel De Gendt; Steven Boonen; Jill Ophoff; Roger Bouillon; Johannes V Swinnen; Guido Verhoeven; Dirk Vanderschueren Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Hang Lee; Joel S Finkelstein; Megan Miller; Sarah J Comeaux; Rachel I Cohen; Benjamin Z Leder Journal: J Clin Endocrinol Metab Date: 2005-12-13 Impact factor: 5.958
Authors: Howard A Fink; Susan K Ewing; Kristine E Ensrud; Elizabeth Barrett-Connor; Brent C Taylor; Jane A Cauley; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2006-07-18 Impact factor: 5.958
Authors: Maya Styner; Gabriel M Pagnotti; Cody McGrath; Xin Wu; Buer Sen; Gunes Uzer; Zhihui Xie; Xiaopeng Zong; Martin A Styner; Clinton T Rubin; Janet Rubin Journal: J Bone Miner Res Date: 2017-05-04 Impact factor: 6.741
Authors: Peter J Snyder; David L Kopperdahl; Alisa J Stephens-Shields; Susan S Ellenberg; Jane A Cauley; Kristine E Ensrud; Cora E Lewis; Elizabeth Barrett-Connor; Ann V Schwartz; David C Lee; Shalender Bhasin; Glenn R Cunningham; Thomas M Gill; Alvin M Matsumoto; Ronald S Swerdloff; Shehzad Basaria; Susan J Diem; Christina Wang; Xiaoling Hou; Denise Cifelli; Darlene Dougar; Bret Zeldow; Douglas C Bauer; Tony M Keaveny Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: Melanie Schorr; Anne Drabkin; Micol S Rothman; Erinne Meenaghan; Gillian T Lashen; Margherita Mascolo; Ashlie Watters; Tara M Holmes; Kate Santoso; Elaine W Yu; Madhusmita Misra; Kamryn T Eddy; Anne Klibanski; Philip Mehler; Karen K Miller Journal: Clin Endocrinol (Oxf) Date: 2019-04-01 Impact factor: 3.478
Authors: Alexander P Taylor; Hang Lee; Matthew L Webb; Hadine Joffe; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2016-06-14 Impact factor: 5.958